撰文丨王聪 编辑丨王多鱼 排版丨水成文 从 代谢功能障碍相关脂肪性肝病 （MASLD） 发展到 代谢功能障碍相关脂肪性肝炎 （MASH） 的过程，会导致肝脏迅速且往往是不可逆的损伤，这凸显了创新 治疗策略的迫切需求。 2026 年 3 月 2 日， 上海交通大学医学院附属第六人民医院转化医学中心/上海市糖尿病重点实验室 贾伟 教授 、 郑晓皎 教授团队 （ 唐雅珺 、 况俊良 为论文 共同第一作者） 在 Cell Metabolism 期刊发表了题为： Targeting microbiota-generated acetaldehyde to prevent progression of metabolic dysfunction- associated steatotic liver disease 的研究论文。 该研究表明， 高糖饮食 下， 肠道微生物 会 产生 内源性乙醛 ，从而在没有酒精摄入的情况下损伤肝脏， 加速 MASLD 向 MASH 的发展。研究团队进一步发现 并通过合成生物学改造了能够清除乙醛的益生菌，在临床前模型中 有效减轻了肝纤维化和炎症。 这项研究不仅 突破 了肝病发病机制的认知 界 ...

Core Viewpoint - Ribocure Pharmaceuticals AB, a subsidiary of Ribocure Bio-B (06938), has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals, Inc. to develop innovative siRNA therapies targeting metabolic dysfunction-related fatty liver disease (MASH) using Ribocure's RiboGalSTAR™ platform [1] Group 1 - Ribocure Bio-B's stock rose over 13%, specifically by 13.65%, reaching HKD 79.95 with a trading volume of HKD 6.4582 million [1] - The agreement allows Madrigal Pharmaceuticals exclusive rights for the global research, production, and commercialization of multiple clinical-stage siRNA assets in the MASH field [1] - Ribocure Bio-B will receive an upfront payment of USD 60 million and is eligible for up to USD 4.4 billion in total payments, including milestone payments related to clinical development, regulatory approval, and commercial sales [1]

Core Viewpoint - The study highlights the role of hepatic GPR110 in the sex-specific development of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH), suggesting it as a potential target for female-specific therapies [4][8]. Group 1: Research Findings - GPR110 is identified as a liver-specific G protein-coupled receptor (GPCR) that is closely related to MASH in a sex-specific manner [6]. - The knockout of the Gpr110 gene in liver cells protects female mice from MASH, while having no effect on male mice [6]. - The variant rs937057 T>C of GPR110 is associated with a higher prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in women [6]. Group 2: Mechanism of Action - GPR110 couples with Gαs to activate protein kinase A (PKA), which induces phosphorylation of NFAT2, inhibiting its nuclear translocation and transcriptional activity, leading to suppression of Esr1 transcription in liver cells [6][8]. - Reducing Gpr110 expression in liver cells improves the liver pathology in female MASH mice, while knocking down estrogen receptor α (Esr1) negates this improvement [6]. Group 3: Implications for Therapy - The findings suggest that inhibiting GPR110 may represent a gender-specific therapeutic approach for MASH, emphasizing the need for targeted treatments based on sex differences [4][8].

Core Viewpoint - The article discusses the discovery of a novel membraneless organelle called Lipid-induced granule (LIG) in hepatocytes, which is induced by lipid accumulation and has implications for understanding liver fibrosis and potential intervention targets for fatty liver disease [3][9]. Group 1: Discovery and Characteristics of LIG - A new type of membraneless organelle, named Lipid-induced granule (LIG), has been identified in hepatocytes, revealing its characteristics, formation, and function [3]. - LIG is formed through the liquid-liquid phase separation (LLPS) of the DDX49 protein, which is induced by lipid metabolites, particularly arachidonic acid [10]. Group 2: Mechanism of Action - LIG plays a role in inhibiting the progression of metabolic dysfunction-associated fatty liver disease (MASLD) by feedback inhibition of the pro-fibrotic liver factor TIMP2 [10]. - The mechanism involves the recruitment of m5C-modified Timp2 mRNA and its reader YBX1 to LIG, which suppresses the translation of Timp2 mRNA, thereby inhibiting liver fibrosis [7][10]. Group 3: Clinical Relevance - The presence of LIG has been identified in human MASLD livers, and its abundance is negatively correlated with the progression of fibrosis [8]. - The global prevalence of MASLD is estimated to be 30% among adults, with its severe form, MASH, leading to liver fibrosis and significant health risks [6].

Core Viewpoint - The company, Xinlitai (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its innovative drug SAL0145 injection, which targets Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) [1] Group 1: Product Development - SAL0145 is an innovative drug developed by the company, aimed at treating MASH, a severe form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1] - MASH affects approximately 30% of the adult population globally, and if left untreated, it can progress to cirrhosis or liver cancer, posing significant health risks to patients [1] - Preclinical studies indicate that SAL0145 has the potential to treat MASH, and successful development and approval could provide new treatment options for patients, addressing unmet clinical needs [1] Group 2: Market Implications - The approval of SAL0145 would enrich the company's pipeline of innovative products in the chronic disease sector, potentially enhancing its market position [1]

Core Insights - The article discusses the increasing global health issue of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), highlighting its progression to Metabolic Dysfunction-Associated Steatohepatitis (MASH) and the associated risks of morbidity and mortality [1][4]. Group 1: Research Findings - A recent study published in Cell Reports Medicine identified blood metabolic panels that can detect significant fibrosis and inflammation in MASLD patients, revealing key metabolites such as Guanidinoacetic Acid (GAA) and Decanoic Acid (SA) that show therapeutic potential in mouse models [2][5]. - The research involved 293 participants across three independent cohorts, utilizing machine learning techniques to develop a non-invasive diagnostic model for detecting significant fibrosis (≥F2) and moderate to severe inflammation (≥I2) [4]. - The area under the receiver operating characteristic curve (AUROC) for fibrosis detection reached 0.928, 0.829, and 0.806 in the discovery, validation cohort 1, and validation cohort 2, respectively, outperforming existing indices like FIB-4 and APRI [4]. Group 2: Implications for Diagnosis and Treatment - The study's findings provide a systematic exploration of the key metabolic features of MASLD, paving the way for new non-invasive diagnostic and treatment strategies [7]. - The identified metabolites GAA and SA can improve liver fat deposition, inflammation, and fibrosis through dual mechanisms of "regulating lipid metabolism" and "promoting inflammation resolution," indicating their potential in advancing MASLD management [5].

Core Insights - Altimmune, Inc. announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks [2][3] Group 1: Trial Results - Statistically significant improvements in key non-invasive markers of fibrosis, including Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), were observed across treatment arms compared to placebo [3][5] - The 1.2 mg and 1.8 mg doses of pemvidutide achieved mean reductions in ELF of -0.49 and -0.58 respectively, versus +0.16 in placebo (p<0.0001) [5] - The 1.2 mg and 1.8 mg doses achieved mean reductions in LSM of -3.04 (p<0.05) and -3.97 (p<0.001) respectively, compared to -0.03 in placebo [5] - Participants receiving pemvidutide also showed significant reductions in liver fat content, alanine aminotransferase (ALT), and corrected T1 (cT1) [5] - Weight loss was observed with the 1.2 mg and 1.8 mg doses at 4.5% and 7.5% respectively, compared to 0.2% in placebo (p<0.0001) [13] Group 2: Tolerability and Safety - The tolerability profile of pemvidutide was favorable at 48 weeks, with low treatment-related discontinuation rates of 0% and 1.2% for the 1.2 mg and 1.8 mg doses respectively, compared to 3.5% for placebo [13] - No serious or severe adverse events related to treatment were reported [13] Group 3: Regulatory Progress - The company held a productive End-of-Phase 2 meeting with the FDA, aligning on parameters for a registrational Phase 3 trial for pemvidutide in MASH patients with moderate to advanced liver fibrosis [6][7] - The FDA's qualification of AIM-MASH AI Assist was noted, which aims to standardize histologic assessment in the Phase 3 trial [6] Group 4: Future Plans - The company plans to initiate the Phase 3 program for pemvidutide in 2026, leveraging the strong evidence of antifibrotic improvements and favorable tolerability [7]

Core Insights - The article discusses the increasing public health burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its progression to Metabolic Dysfunction-Associated Steatohepatitis (MASH), highlighting limited treatment options [2] - A study published in Cell Metabolism reveals that the diene acid analog 326E alleviates MASH by dual targeting ACLY and PPARα, demonstrating its therapeutic potential and good tolerability in human clinical trials [2][5] Group 1: Mechanism and Efficacy - The diene acid ATP-citrate lyase (ACLY) inhibitor 326E significantly reduces liver lipid accumulation and alleviates MASH symptoms in mouse models [3] - 326E works by inhibiting ACLY to decrease de novo lipogenesis (DNL) and acts as an allosteric modulator of PPARα to enhance fatty acid oxidation (FAO), thus addressing MASH [3][8] - The study confirmed the preventive effects of 326E on MASH in non-human primates, further supporting its potential as a treatment [4] Group 2: Clinical Trials and Results - A randomized 1b/2a phase clinical trial in human MASH patients (NCT06491576) showed that 326E has good tolerability and lowers levels of γ-glutamyl transferase (γ-GGT), a key biomarker for liver disease [5][9] - The results from preclinical studies in mice and non-human primates, along with human clinical trials, indicate that 326E has therapeutic potential for MASH through its unique mechanisms of action [8]

Core Viewpoint - Novo Nordisk has reached a final agreement to acquire Akero Therapeutics for up to $5.2 billion, with a cash offer of $54 per share and an additional contingent value right of $6 per share, pending regulatory approval of Akero's drug efruxifermin [1][2] Group 1: Acquisition Details - The total acquisition price is up to $5.2 billion, consisting of $4.7 billion in cash and a $500 million contingent value right [1] - The deal has been unanimously approved by Akero's board and is expected to close by the end of the year [1] - Following the announcement, Akero's stock surged nearly 18%, while Novo Nordisk's stock fell over 1% [1] Group 2: Akero Therapeutics and Efruxifermin - Akero is a clinical-stage biopharmaceutical company focused on developing therapies for patients with severe metabolic diseases [1] - Efruxifermin is currently undergoing late-stage trials aimed at treating patients with moderate to advanced liver fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH) [1] - MASH can progress from metabolic dysfunction-associated steatotic liver disease (MASLD) and is characterized by steatosis, inflammation, and fibrosis, potentially leading to cirrhosis [1] Group 3: Strategic Implications - Novo Nordisk's CEO emphasized the potential of efruxifermin to reverse liver damage and become a cornerstone therapy, either alone or in combination with Wegovy [2] - Akero believes that Novo Nordisk's global leadership in metabolic diseases will accelerate the evaluation and commercialization of efruxifermin [2] - A contingent payment of $6 per share will be made to Akero shareholders if efruxifermin receives full approval from U.S. regulators by June 30, 2031 [2]

Core Viewpoint - Roche is strengthening its position in the cardiovascular, renal, and metabolic diseases (CVRM) sector through the acquisition of 89bio for $3.5 billion, securing the innovative MASH drug Pegozafermin, which is currently in Phase III clinical trials [1][10]. Group 1: Acquisition Details - Roche's acquisition of 89bio focuses on Pegozafermin, which has the potential to generate peak sales exceeding $5 billion, as the global MASH drug market is projected to reach $35 billion by 2030 [1][2]. - The acquisition agreement includes a base price of $14.50 per share plus up to $6 per share in contingent value rights (CVR), potentially bringing the total deal value to $3.5 billion [4][8]. - The CVR stipulates additional payments based on Pegozafermin achieving specific sales milestones, potentially adding up to $1 billion for 89bio's shareholders [5][6][7]. Group 2: Market Potential and Demand - MASH affects an estimated 5%-7% of the adult population globally, with significant unmet clinical needs, particularly in China and the U.S., where the number of patients is expected to rise substantially by 2032 [2][4]. - The MASH treatment landscape has seen numerous failures, making Pegozafermin's potential as a first-in-class therapy particularly promising [4][19]. Group 3: Roche's CVRM Strategy - Roche's CEO emphasized that the acquisition enhances the company's CVRM product portfolio and opens opportunities for combination therapies with existing projects [11]. - Roche has a diverse pipeline in the CVRM space, including several promising candidates such as GLP-1 drugs and RNAi therapies, indicating a strategic focus on this area for future growth [14][16][17]. - The company has invested in multiple potential blockbuster drugs, including Petrelintide and Zilebesiran, to solidify its position in the metabolic and cardiovascular markets [17][19]. Group 4: Competitive Landscape - The MASH treatment field is highly competitive, with over 60 active clinical trials and multiple candidates from major pharmaceutical companies, highlighting the intense research activity in this area [19][22]. - Roche's strategic investments and acquisitions are aimed at building a comprehensive network in the CVRM sector, positioning the company for significant growth in this rapidly evolving market [22][23].